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ABSTRACT
Aptamers that can be regulated with light allow
precise control of protein activity in space and
time and hence of biological function in general. In
a previous study, we showed that the activity of the
thrombin-binding aptamer HD1 can be turned off by
irradiation using a light activatable ‘caged’ intra-
molecular antisense-domain. However, the activity
of the presented aptamer in its ON state was only
mediocre. Here we studied the nature of this loss in
activity in detail and found that switching from 50-t o
30-extensions affords aptamers that are even more
potent than the unmodified HD1. In particular we
arrived at derivatives that are now more active
than the aptamer NU172 that is currently in phase
2 clinical trials as an anticoagulant. As a result,
we present light-regulatable aptamers with a
superior activity in their ON state and an almost
digital ON/OFF behavior upon irradiation.
INTRODUCTION
Aptamers are short single-chain nucleic acids that fold
into well-deﬁned three-dimensional structures. They can
be identiﬁed by an in vitro selection approach, also
termed SELEX (systematic evolution of ligands by expo-
nential enrichment) (1,2). To a large variety of target
molecules this approach has been applied, yielding selec-
tive aptamers. One of the most prevalent classes of target
molecules is proteins. Due to their sophisticated inhibitory
capabilities, aptamers promise to be an excellent novel
class of therapeutic molecules and one aptamer, namely
Macugen, which binds to vascular endothelial growth
factor (VEGF) thereby inhibiting its interaction with the
VEGF-receptor is approved by the FDA for the treatment
of the wet form of age-related macular degeneration (3).
Since the ﬁrst description of aptamers, many eﬀorts
have been undertaken to develop thrombin-targeting
aptamers for the use as anticoagulants (4–6). In this
regard, the 15 nucleotides minimal motif of an anti-
thrombin aptamer (HD1, Figure 1a), initially described
by Bock et al. in 1992, raised huge attention and repre-
sents today one of the most intensively studied aptamers
(7). Albeit clinical trials to verify the aptamer’s eﬀective-
ness as anticoagulant have been halted after phase I, the
aptamer has been used by many researchers for structural
and diagnostic investigations what is mainly due to its
simple composition and G-quadruplex structure. The
latter has led to many studies analyzing the structure,
and NMR, circular dichroism (CD) spectroscopy, native
polyacrylamide gel electrophoresis, molecular dynamic
simulation and crystallography have been used to
address the conformation of this G-quadruplex and the
basis for its interaction with thrombin. These show that
HD1 folds into an intramolecular quadruplex with an
antiparallel orientation of the strands in a chair-like
conformation (Figure 1a).
We have recently started to develop generic approaches
aiming at the control of nucleic acid function by light in
space and time. This generic approach allows interfering
with gene expression and protein function in arbitrary
regions and at well-deﬁned points in time and proﬁts
from the fact that light is an ‘orthogonal’ and harm-
less trigger signal—if applied correctly—and that many
relevant living samples are light-accessible (8–12). One
way to introduce light-control is by attaching photolabile
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concept to nucleic acids we have for example already
developed light activatable siRNAs (13) and showed that
it is possible to induce transcription with light (14).
To demonstrate the concept of controlling protein
function in time and space using the aptamer approach,
we deﬁned and synthesized variants of HD1 whose
thrombin interacting activity can be controlled by light.
For the reasons given above, HD1 is an ideal candidate.
To make HD1 light-inducible, based on the co-crystal
structure of the HD1–thrombin complex (PDB code:
1HAO, Figure 1a), we introduced a photolabile group at
a strategic position of the aptamer to temporarily inhibit
the interaction with thrombin. The modiﬁcation of T4 in
HD1 with such a photolabile caging group that prevents
this residue from forming the natural nucleobase interac-
tion led to a derivative that could be eﬀectively turned ON
upon irradiation with UV-A light (15). Later, we showed
that this is also possible by light-induced formation of
the G-quadruplex conformation (16,17). In an ongoing
endeavor, we also started designing variants of the
aptamer that could be turned OFF by UV-A light
exposure. Therefore, we extended the 50-terminal region
of HD1 with sequences supposed to form a hairpin-like
structure stabilized by a GNRA-tetraloop (aptamers 1
and 2, Figure 1b, residues that are intended antisense
residues are underlined in the sequences) (18). It could
be shown that four antisense residues (such as in
aptamer 1) were suﬃcient to make HD1 completely
inactive. To make this conformational transition light-
inducible, we subsequently placed a caged residue at
C4 in the aptamer sequence (aptamer 3). Figure 1b
shows the caged residue dC
NPE that has been used in
that study and that is abbreviated as C* in a one-letter
code representation here. The nucleobase carries a
photolabile o-nitrophenylethyl (NPE) group that makes
C* a mismatch until irradiation upon which an unmodi-
ﬁed cytidine is formed. Thus we constructed a novel
anticoagulant with a built-in antidote activity that can
be released upon light irradiation. However, although
we demonstrated for the ﬁrst time that an aptamer can
be inactivated with light the inhibitory potential of
aptamer 3 in coagulation assays did not reach the one of
the unmodiﬁed HD1. Here we systematically address
this observation by the comparison of HD1 variants that
bear various extensions either at their 50-o r3 0-terminal.
Unexpectedly, we found that 50-extensions lead to a
dramatic loss in activity whereas the same extensions
at the 30-end resulted in even more potent aptamers
compared with the parent aptamer HD1. Ultimately,
these ﬁndings led to the design and synthesis of
improved second generation caged aptamers that were
found to be more active than HD1 and could be eﬃciently
turned OFF upon light irradiation.
MATERIALS AND METHODS
Oligonucleotide synthesis
Unmodiﬁed oligonucleotides were purchased from
Microsynth, Balgach (Switzerland) (www.microsynth.ch),
and had been HPLC puriﬁed. The amidites dC
NPE and
dA
NPE were used with regular solid phase synthesis
protocols on an ABI-392 synthesizer. For the cleavage
either aqueous ammonia (65 C, 4h) or a 1:1 mixture of
aqueous ammonia and methyl amine (1:1, room tempera-
ture, overnight) was used. The resulting crude product was
puriﬁed by RP-HPLC (Nucleosil 100-5, C18, 0.1M
triethylammonium acetate pH 7, acetonitrile), detritylated
and again puriﬁed by RP-HPLC (same protocol).
The identity of the oligonucleotides has been
established by ESI: aptamer 3: 7350.0Da (expected
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Figure 1. (a) Cartoon representation of the antiparallel quadruplex structure of the thrombin-binding aptamer HD1 and of HD1 bound to thrombin
(PDB code: 1HAO). Thrombin is shown as surface with negatively charged areas colored in red and positively in blue. (b) Top: Cartoon represen-
tation of the light-induced inactivation of HD1. Middle: The aptamers 1–3 with designed intramolecular antisense residues (underlined) have been
part of a previous study in which we already showed that it is possible to turn the activity of HD1 OFF by irradiation with light (18). Shown are also
the residues dC
NPE and dA
NPE (bottom). The former has been introduced in our previous study (18) while the latter is introduced here. Both residues
have photolabile NPE groups (o-nitrophenylethyl) that keep them from forming normal nucleobase interactions until irradiation and can thus mask
nucleotide activity that can be restored with control of space and time.
2112 Nucleic Acids Research, 2010,Vol.38, No. 6average: 7348.8Da), aptamer 26: 7767.2Da (expected
exact: 7767.4Da), aptamer 27: 8056.6Da (expected exact:
8056.4Da), aptamer 28: 8588.3Da (expected
exact: 8588.5Da), aptamer 29: 8886.1Da (expected exact:
8886.6Da), aptamer 30: 8742.3Da (expected average:
8741.8Da).
Irradiation
For the uncaging the respective aptamers were irradiated
for 3min with three UV-LEDs (Nichia NCCU033,
360nm, 100mW each) operated at 0.5 A.
Plasma coagulation assay
The anticoagulant activity of the aptamers was measured
in a one-stage plasma-based coagulation assay
[thrombin-time (TT)] using an ACL Top coagulation
analyser (IL, Kirchheim, Germany). In brief, human
a-thrombin (CellSystems, St. Katharinen, Germany) was
diluted in the assay buﬀer (1 PBS, pH 7.4, 3mmol/l
MgCl2,1mg/ml BSA) to reach a ﬁnal concentration of 10
NIHU/ml (75nmol/l). This thrombin solution was spiked
with aptamers at a ﬁnal concentration of 1mmol/l and
75ml of the reaction mixtures were added to prewarmed
cuvettes of the ACL-analyzer. After incubation for 1min
at 37 C, 75ml of pooled normal human plasma was added
and clotting times measured. For comparative determina-
tion of the thrombin-inhibiting capacity of the tested
aptamers, clotting times were normalized to standard
curves as determined by serial dilutions of a-thrombin in
a concentration range from 10 NIHU/ml (100%) down to
0.625 NIHU/ml (6.25%). To assess the anticoagulant
activity of the aptamers relative to that of HD1, clotting
times were normalized to that of HD1-standard curves [0
(0%) to 2mmol/l (200%)] processed in parallel.
CD spectroscopy
To obtain CD spectra 1nmol of the respective aptamers
was dissolved in 110ml of PBS buﬀer (ﬁnal concentrations
137mM NaCl, 2.7mM KCl, 10mM phosphate, pH 7.4).
The spectra were measured on a JASCO J-715 and are
background-subtracted and smoothed.
Filter retention assay
For ﬁlter retention analysis, aptamers were 50-end labeled
with g
32P-ATP using T4 polynucleotide kinase
(Stratagene, Amsterdam, Netherlands) for 45min at
37 C. Subsequently, the reaction mixture was applied to
G25 microspin columns (GE Healthcare, Munich,
Germany) to remove unreacted g
32P-ATP and the
resulting ssDNA was analyzed on 12% polyacrylamide
gels to check the integrity. For determination of dissocia-
tion constants, radioactively labeled aptamers at a ﬁnal
concentration of 0.5nM were incubated with increasing
amounts of bovine thrombin (0–1mM). Generally, exper-
iments were performed in PBS, pH 7.3, containing 2mM
tRNA. After incubation at 37 C for 30min, the reaction
mixtures were ﬁltered through a wet 0.45mm nitrocellulose
membrane (Schleicher and Schuell, Dassel, Germany) and
washed with 0.8ml washing buﬀer (PBS, pH 7.3). After
drying, the membrane was exposed on a storage phosphor
screen and analyzed on a FUJIFILM FLA-3000 with
the AIDA Imagequant software (Fujiﬁlm, Du ¨ sseldorf,
Germany). The dissociation constants were calculated
using a logistic ﬁt function assuming a 1:1 binding
stoichiometry of aptamer–protein complexes.
RESULTS AND DISCUSSION
Figure 2 shows the performance of the various derivatives
of HD1 in the coagulation assays. The results are given in
two scales. For one the activity of the aptamer variants is
displayed as percentage of the activity of the parent
aptamer HD1 (Figure 2, black bars). The other scale rep-
resents the percentage of residual thrombin activity in the
presence of the indicated aptamers (Figure 2, grey bars).
Both scales are reciprocal to each other. Normalization of
raw data (clotting-times) to corresponding thrombin-
and HD1-activites was a prerequisite for accurate evalua-
tion of the tested aptamer variants. This is due to the
typical non-linear correlation between both thrombin- or
inhibitor-activity and resulting clotting times (Supple-
mentary Data). Under the conditions chosen, the applica-
tion of unmodiﬁed HD1 yielded a residual thrombin
activity of 20%. Aptamer 1 in turn, with a four-nucleotide
50-antisense region and the GAAA-tetraloop sequence had
no anti-thrombin activity—as intended and as previously
reported (18). A shorter antisense sequence was not
suﬃcient to block aptamer activity, as aptamer 2 with
only two complementary residues retained 12% of the
parental HD1 activity. In the previously mentioned
caged aptamer 3, the antisense region should be blocked
and hence the aptamer should reach 100% HD1 activity
before irradiation. However, it does not, as it only shows
14% activity compared to HD1. Irradiation of 3 on the
other hand results in almost the same values as observed
with aptamer 1 indicating that the uncaging process is
complete. This is also what can be seen in HPLC traces
(Supplementary Data).
On the way to an explanation why aptamer 3 is less
eﬃcient before irradiation as HD1 we tested aptamer 4
with only the GAAA loop region and found that
already by attaching these four nucleotides to the 50-end
the aptamer suﬀers by a reduction of its activity down to
34% on the HD1 scale. Assuming that the adenosine
residues might interfere with the thymidine residues of
HD1, we chose diﬀerent loop sequences (aptamers 5 and
6) and found that the HD1 activity could be somewhat
improved. An aptamer with an AAAA loop (aptamer 7)
performed again similarly as aptamer 4, supporting that
desoxyadenosines are particularly activity impairing at
the 50-end but their possible interaction with the thymidine
residues of HD1 cannot be the only explanation.
Assuming that the nucleotide 50-extension might be
detrimental due to their pi stacking interactions we tried
non-nucleosidic linkers such as abasic sites (aptamer 8),
aliphatic spacers (aptamer 9) and ethylene glycol-derived
spacers (aptamer 10) but 100% HD1 activity could again
not be reached by far.
Nucleic Acids Research,2010, Vol.38, No. 6 2113Initially purely for reference, we also attached linkers to
the 30-end of HD1 (aptamer 11). To our surprise, however,
an aptamer with two more adenosines on the 30-end even
showed an activity that was slightly better than the one of
HD1—signiﬁcant within error limits. The anticoagulant
performance could even be increased by adding more
adenosines and reached a plateau at around six
(aptamers 12 and 13). For reference it shall be noted
that in a previous study, an HD1-derivative with a
30-dA15-extension showed similar activities compared
to HD1 in our assays (19). With four thymidines at
the 30-end (aptamer 14), a similar picture was found.
Exchanging the nucleoside linkers on the 30-end for
abasic sites (aptamer 15 with a phosphate on the 30-end
due to synthesis reasons) resulted in the most potent
aptamer in the entire study and a 1.5-fold increase of
activity compared to HD1 was observed. Therefore,
aptamer 15 is superior to a diﬀerent anti-thrombin
aptamer that also targets exosite I and that is currently
in phase II clinical trials, namely NU172 (Figure 2)
(20). This diﬀerent behavior of opposed terminal exten-
sions of HD1 was especially surprising to us since in the
co-crystal structure of the HD1–thrombin complex the
50- and the 30-ends reside right next to each other
(Figure 1a). Encouraged by these ﬁndings, we started to
address the question whether the activity could again be
turned oﬀ by adding antisense residues—this time to the
30-end. In the 30-adenosine-linker series (aptamers 16–19),
it turned out that adding ﬁve to six antisense residues
reduced the activity of HD1 almost to background
levels. With thymidines as 30-linkers (aptamers 20 and
21), a signiﬁcant activity remained even with six comple-
mentary residues. With abasic sites as 30-linkers (and thus
starting from a higher HD1 activity) nine antisense
residues aﬀorded an aptamer that was cleanly OFF
(aptamers 22–25).
To now obtain caged aptamers with signiﬁcantly
improved diﬀerence in activity between the ON and
OFF state and improved performance in the ON state,
caged residues were introduced in the antisense region.
The caged dC
NPE had already been introduced previously;
however, a similarly caged dA
NPE had never been used
before. Figure 3 shows the synthesis route that we chose
in analogy to the synthesis of the caged ribonucleotide
analogue that had been used in a study by Silverman
et al. (21). In brief, the hydroxyl groups of deoxyinosine
were TBDMS-protected and then O
6 was transferred into
a leaving group by reaction with triisopropylbenze-
nesulfonyl chloride (TPSCl). After nucleophilic attack
with the amine of the caging group (NPE-NH2) and
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Figure 2. Results of coagulation assays with the listed aptamers without or with (hn) irradiation. Clotting times have been normalized toward the
one of HD1. A second—reciprocal—scale is given that shows how much thrombin remained active. The sequence of the aptamer NU172 (used in this
study for comparison reasons) is CGCCTAGGTTGGGTAGGGTGGTGGCG (20). (ab=abasic site, C3=n-propyl spacer nucleotide,
TriEG=triethylene glycol nucleotide, TetEG=tetraethylene glycol nucleotide).
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selective protection of the primary 50-OH group with
dimethoxytrityl chloride (DMTrCl) and introduction of
the phosphoramidite at the 30-OH aﬀorded the protected
building block that could be used in a regular solid phase
synthesis (for more details of the synthesis, see the
Supplementary Data).
The performance of the aptamers with caged
30-extensions are shown in Figure 4. Aptamer 26 with an
adenosine linker, ﬁve antisense residues and two cages
only showed an HD1 activity of 64%. This clearly dem-
onstrates that the eﬀect of the antisense strand is
insuﬃciently masked by the two cages in this case. This
is even more pronounced in aptamer 27 with six antisense
nucleotides and still two cages. Due to the better perfor-
mance of the aptamers with 30-abasic site linkers we then
switched to this series and found that ﬁve or four cages in
the nine-nucleotide antisense region (aptamers 28–30)
performed best. Notably, compared to the aptamer 3 in
our original study, with aptamers 29 and 30, we now
present caged aptamers that even outperform HD1
before irradiation and only show background activity
after irradiation. With four or ﬁve caged residues HPLC
analysis did not provide evidence for incomplete uncaging
(Supplementary Data).
The question remains about the reason for the
signiﬁcantly improved performance of the 30-extended
aptamers. In order to address this question, we performed
CD measurements with the aptamers presented here.
Figure 5a shows the CD spectra of the 50-extended
aptamers. It can clearly be seen that these fall into three
clusters. On the one side there is the spectrum of only HD1
that shows the strong expected signal of the antiparallel
G-quadruplex for example with its maximum around
290nm and its minimum around 270nm (22). The
second cluster consists of the spectra of aptamers 5, 8, 9
and 10, while the third cluster comprises the spectra of
aptamers 4 and 7. These clusters correlate nicely with
the performance of the respective aptamers in the
coagulation assays with HD1 being the best, aptamers 5,
8, 9 and 10 being mediocre and aptamers 4 and 7 being
worst. It appears that especially the latter two aptamers
have a structure in solution that is signiﬁcantly diﬀerent
from the structure of HD1. On the contrary almost all
spectra of the aptamers in the 30-extended series (without
antisense sequence) are very close to the one of HD1 and
aptamer 15—the best in the coagulation series—has a CD
spectrum that comes closest (Figure 5b). The 30-extended
aptamers with antisense residues 18, 19 and 25 do show
completely diﬀerent CD spectra—supporting the expected
conformational transition and explaining the intended loss
in activity.
The CD spectra of the caged aptamers 26–28 look
surprisingly diﬀerent from the one of HD1 and almost
no change upon irradiation is observed (Figure 6a). The
same was true for our original caged aptamer 3. From
these ﬁndings it is surprising that these aptamers still
showed a signiﬁcant anti-thrombin activity before irradi-
ation. However, it might be speculated that upon adaptive
binding to thrombin the conformational equilibrium
between active and inactive structure is still shifted
toward the active one (23). This would not be unexpected
as HD1 has even been used as an aptamer beacon that
folded from a stem–loop structure into a G-quadruplex
structure upon addition of thrombin and was propagated
for the detection of the presence of thrombin (24).
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Figure 4. Results of coagulation assays with the listed aptamers
without or with (hn) irradiation. Clotting times have been normalized
toward the one of HD1. A second—reciprocal—scale is given that
shows how much thrombin remained active.
Nucleic Acids Research,2010, Vol.38, No. 6 2115The caged aptamers 29 and 30, ﬁnally, show a strong
G-quadruplex CD signal before irradiation that correlates
nicely with the ﬁndings in the performed clotting assays.
After irradiation, the CD spectrum changes completely
and results in the same as for aptamer 25 that is consistent
with the observation of the clean uncaging process by
HPLC.
Thus, CD spectroscopy shows that 50- and 30-extended
aptamers (without antisense region) diﬀer signiﬁcantly in
their solution structure already in the absence of
thrombin. As noted previously, this was unexpected
since in the antiparallel structure of the G-quadruplex
both ends are relatively close. To further assess the
source of the diﬀerent behavior of 50- and 30-extensions,
we determined the dissociation constants for some of the
aptamers toward thrombin using ﬁlter retention analyses.
The results are summarized in Table 1. HD1 had a disso-
ciation constant of 88nM toward thrombin while for
aptamer 1 with the 50-antisense region and -linker no inter-
action could be detected, as expected. It is apparent that
the 50-extended aptamers 5, 7 and 8 all aﬀorded dissocia-
tion constants similar to the one of HD1. Notably,
aptamer 7 with four adenosines at the 50-end has literally
the same aﬃnity toward thrombin as HD1 even though in
the functional coagulation assays it performed worst in
the 50-extended series. On the other hand with ﬁlter reten-
tion assays in the case of a mixture of conformations the
dissociation constants of the individual conformers can be
measured in principle even if they are only present in small
quantities. Given the results of the CD measurements it is
likely that in these cases another binding-incompetent
conformation is present in the equilibrium. The
30-extended aptamers 12, 14 and 15 again showed a very
similar dissociation constant to the one of HD1. One
possible reason for the increased eﬃciency of the
30-extensions could have been the addition of negative
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Figure 6. CD spectra of the listed aptamers without or with (hn) irradiation (ab=abasic site, C3=n-propyl spacer nucleotide, TriEG=triethylene
glycol nucleotide, TetEG=tetraethylene glycol nucleotide).
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Figure 5. CD spectra of the listed aptamers (ab=abasic site, C3=n-propyl spacer nucleotide, TriEG=triethylene glycol nucleotide,
TetEG=tetraethylene glycol nucleotide).
2116 Nucleic Acids Research, 2010,Vol.38, No. 6charges to the aptamer that enhances the interaction with
thrombin electrostatically. Looking at Figure 1a it is
apparent that in the vicinity of the 30-end of the
aptamer, thrombin displays quite a number of positively
charged residues. However, they should also be reachable
by negatively charged 50-extensions and indeed the
ﬁndings of the KD-measurements suggest that electrostatic
interaction is not the source for the enhanced aﬃnity. For
the 30-extended aptamers with antisense regions 18, 19 and
25, again no interaction with thrombin was observed, as
expected. The results with aptamers 23 and 24 demon-
strate once more what has just been mentioned. A KD
value in the same region as the one of HD1 was deter-
mined even though both aptamers are already signiﬁcantly
under the inﬂuence of the antisense region in the
coagulation assay. However, here the transition from the
binding-competent conformation to an incompetent one is
intended and only the KD value of the binding-competent
conformation in the equilibrium is determined. In the set
of caged aptamers (26–30), the KD values have a tendency
to be somewhat lower in most of the cases in comparison
with HD1—again despite the fact that aptamers 28 and 29
are in fact the best caged aptamers of the entire study. This
demonstrates that the reason for the improved
performance is not the aﬃnity.
In summary we have demonstrated that there is a sub-
stantial diﬀerence in anti-thrombin aptamer performance
between 50- and 30-extended derivatives—even if the same
sequences are used. 30-extended aptamers even improve
the activity of HD1 while 50-extensions are detrimental.
According to our data, the reason is not a signiﬁcant
change in aﬃnity toward thrombin but rather a structural
transition that happens in the aptamer itself even in the
absence of thrombin that cannot be rescued by adaptive
binding. The data presented here provide strong evidence
that modiﬁcations of aptamers or any other functional
nucleic acid can have a very strong impact on their per-
formance. Previous studies already pointed toward this
direction for aptamer HD1 but did not investigate this
in greater detail (25,26). Thus, the data presented here
provide a comprehensive view on aptamer dependence
on opposed terminal extensions and give rise to variants
that were 1.5-fold more active as the parental aptamer
(HD1) and even more active as a second generation
exosite I targeting aptamer (NU172) currently under
investigation in clinical trials (20). As a further result,
we present now caged HD1 derivatives that are light-
responsive and that before irradiation are more active
than HD1 and after irradiation are cleanly turned OFF
and do not show any interaction with thrombin anymore.
Thereby we are able to eﬃciently design aptamers with
an inherent antidote function without loss of aptamer
activity and a clean OFF behavior. The design of
antidote molecules is a major task in molecular medicine
and within this ﬁeld potent strategies to control aptamer
activity have been developed (4,27). Our ﬁndings have a
strong impact on the design of hemostyptic and tumor
occluding agents, which seek to employ aptamers to tem-
porarily control thrombin activity but upon light irradia-
tion releasing native thrombin quantitatively. In contrast
to recently reported reversible light-dependent approaches
that result only in marginal regulation eﬃciency (28), the
ﬁndings here can be considered almost digital (as 1 and 0).
The dichotomy as to why 50-extensions lead to diﬀerent
conformations as opposed to 30-extensions cannot be fully
explained in the current study and suggests thorough
investigation for example by NMR in solution. Our
study therefore suggests further investigation by dynamic
NMR to investigate the relationship between extensions,
aptamer conformation and adaptive target binding in
greater detail.
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